belzutifan,pembrolizumab,cabozantinib
exelixis,merck
['lite,spark-003', 'rcc,(-irccs),(-srcc),(-urcc)', ' cabo ']
litespark-003: cabo + belzu phase ii trial in 1l therapy for mrcc. encouraging activity data for this combination. #esmo22 
Medical Oncologist - Urologic Oncology. Hospital Universitario La Paz - IdiPAZ, Madrid